KFDA to Request Additional Data on Hanmi's Anti-Obesity Drug

Published: 2005-03-22 06:57:00

Updated: 2005-03-22 06:57:00

According to an industry source, the Korea Food and Drug Administration (KFDA) is to request Hanmi Pharmaceuticals to make an additional data provision for its anti-obesity drug Slimer (active ingredient: sibutramine mesylate), which was originally submitted for approval in December of last year....

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK